Triple Treatment Combo Beneficial in BRAF-Mutant CRC
Irinotecan, cetuximab, and vemurafenib improve progression-free survival in BRAFV600E-mutated colorectal cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.